Variant Creutzfeldt-Jakob Disease (vCJD) is a rare, fatal, neurodegenerative disorder caused by exposure to bovine spongiform encephalopathy (BSE) prions, commonly known as "mad cow disease." Unlike sporadic CJD, vCJD predominantly affects younger individuals and has a distinct clinical and neuropathological phenotype. It is the human form of BSE and represents the first recognized example of a prion disease crossing species barriers to cause epidemic spread in humans. @plaquetype
¶ History and Discovery
vCJD was first described in 1996 in the United Kingdom, where it emerged nearly a decade after the BSE epidemic in cattle peaked 1, 2. The link between BSE and vCJD was established through epidemiological studies, neuropathological comparisons, and later confirmed by laboratory transmission studies showing that the vCJD prion strain is indistinguishable from the BSE prion 3, 4. The identification of vCJD provided critical evidence that prions could jump species barriers and cause novel diseases in humans. @antibodies
- United Kingdom: The vast majority of vCJD cases (n=178) occurred in the UK, with the epidemic peaking in 2000 [5]
- France: Second highest number of cases (n=27)
- Other countries: Cases reported in Ireland, Italy, Spain, Netherlands, USA, Canada, Japan, and others (total ~230 worldwide)
¶ Age and Sex Distribution
- Mean age at onset: 28 years (range 12-74 years)
- Sex ratio: Slight male predominance (M:F ≈ 1.2:1)
- Peak incidence: Ages 20-30 years
- Dietary exposure: Consumption of BSE-contaminated beef products, particularly neural tissue
- Geographical exposure: Residence in countries with BSE epidemics during 1980-1996
- Genetic susceptibility: Homozygosity at PRNP codon 129 (methionine/methionine) associated with increased susceptibility [6]
vCJD is caused by the same prion strain (BSE) that causes mad cow disease. The infectious agent is an abnormal isoform of the prion protein (PrP^Sc) that catalyzes the conversion of the normal cellular prion protein (PrP^C) to the disease-associated form [7]. @prion
| Feature | vCJD | Sporadic CJD | @strain
|---------|------|--------------| @epidemiology
| Age at onset | Younger (mean 28) | Older (mean 65) | [^6]
| Disease duration | Longer (median 14 months) | Shorter (median 4 months) | [^7]
| Clinical presentation | Psychiatric/behavioral early | Dementia/cerebellar early | [^8]
| PRNP codon 129 | Predominantly MM | Variable | [^9]
| Pulvinar sign | Characteristic on MRI | Rare | [^10]
| Prion distribution | Lymphoreticular involvement | CNS primarily | [^11]
- Prion conversion: The BSE prion template directs the conversion of human PrP^C to PrP^Sc
- Glycoform ratio: vCJD PrP^Sc has a distinctive 3-band pattern on Western blot
- Strain typing: Different from sCJD, GSS, and FFI strains [8]
- Psychiatric manifestations: Depression, anxiety, social withdrawal, apathy
- Behavioral changes: Personality changes, irritability
- Persistent pain: Often severe, poorly localized pain or dysesthesia
- Sleep disturbances: Insomnia, sleep reversal
- Cognitive decline: Progressive dementia, memory impairment
- Cerebellar signs: Ataxia, gait disturbance, dysarthria
- Movement disorders: Myoclonus, dystonia, parkinsonism
- Visual symptoms: Diplopia, visual field defects, cortical blindness
- Severe neurological decline: Akinetic mutism, complete motor impairment
- Myoclonus: Often stimulus-sensitive
- Death: Typically from aspiration pneumonia or other complications
Definite vCJD: [^12]
- Neuropathological confirmation of vCJD
- OR positive PrP^Sc detection in tonsil or other lymphoid tissue
Probable vCJD: [^13]
- Progressive neuropsychiatric disorder
- Plus 4 of the following:
- Early psychiatric symptoms (depression, anxiety, apathy, delusions)
- Persistent painful sensory symptoms
- Ataxia
- Myoclonus or chorea/dystonia
- Dementia
- Plus "pulvinar sign" on MRI
- OR positive tonsil biopsy
Possible vCJD:
- Progressive neuropsychiatric disorder
- Plus 3 of the following:
- Early psychiatric symptoms
- Persistent painful sensory symptoms
- Ataxia
- Myoclonus or chorea/dystonia
- Dementia
MRI Brain:
- Pulvinar sign: High signal in posterior thalamus (pulvinar) on T2/FLAIR imaging
- Cortical involvement: Hyperintense signal in cerebral cortex, particularly occipital
- Basal ganglia: Occasionally involved [9]
CSF Analysis:
- 14-3-3 protein: Positive in ~70% of cases
- Total tau: Elevated
- Neuronal degeneration markers
Tonsil Biopsy:
- Immunohistochemical detection of PrP^Sc in lymphoid follicles
- Western blot analysis for PrP^Sc
PRNP Gene Analysis:
- Codon 129 genotyping (predominantly methionine homozygous)
- No pathogenic mutations (distinguishes from familial CJD)
- Kuru-type amyloid plaques: Prion amyloid plaques surrounded by vacuolation
- Florid plaques: Large, multi-centric plaques with eosinophilic cores and peripheral spongiform changes
- Diffuse amyloid deposits: PrP immunoreactivity throughout the neuropil
- Spongiform change: Vacuolation particularly in basal ganglia, thalamus, and cerebral cortex
- Neuronal loss: Progressive loss of neurons
- Gliosis: Astrocytic and microglial proliferation [10]
- Tonsils: PrP^Sc detected in follicular dendritic cells
- Spleen: Significant prion accumulation
- Lymph nodes: Involvement in all lymph node groups
- Appendix, tonsil: Useful biopsy targets for antemortem diagnosis [11]
There is no disease-modifying treatment for vCJD. Management is supportive and palliative.
Symptomatic Management:
- Psychiatric symptoms: SSRIs, atypical antipsychotics
- Myoclonus: Clonazepam, valproic acid, levetiracetam
- Seizures: Antiepileptic medications
- Pain: Multimodal analgesia including opioids
- Nutritional support: PEG tube feeding as disease progresses
Palliative Care:
- Multidisciplinary palliative care team involvement
- Early discussion of advance directives
- Management of respiratory complications
- Psychological support for family [12]
- Antemortem diagnosis: Improving early detection through tonsil biopsy
- Therapeutic trials: Currently no proven effective therapy
- Prion-inhibiting compounds: Quinacrine, pentosan polysulfate (not proven effective)
- Median survival: 14 months (range 6-39 months)
- Outcome: Uniformly fatal
- Age correlation: Younger patients tend to have longer survival
- PRNP 129MM: Associated with earlier age of onset and shorter survival
The emergence of vCJD led to:
- Massive BSE surveillance in cattle
- Feed bans prohibiting meat-and-bone meal in cattle feed
- Specified risk material (SRM) removal regulations
- Beef import restrictions from BSE-affected countries
¶ Blood and Tissue Safety
- vCJD has caused concern about blood product safety
- Donor deferral policies for residents of countries with high BSE exposure
- Leukodefiltration of blood products
- Tissue and organ donation restrictions
- Subclinical carriers: Asymptomatic individuals with prion infection
- Secondary transmission: Blood transfusion, contaminated surgical instruments
- Long incubation period: Cases may still emerge from earlier exposure [13]
Variant CJD represents a unique chapter in prion disease research, demonstrating the ability of animal prions to cross species barriers and cause human disease. The epidemic, though small in absolute numbers, has had profound impacts on public health policy, blood safety, and our understanding of prion biology. Continued surveillance remains essential given the long incubation periods and potential for secondary transmission.
This section highlights recent publications relevant to this disease.